Loading
companiesCompany
SpeciCare
SpeciCare preserves a patient's living tumour tissue at biopsy or surgery so it can be used later for testing, including treatments that may not exist yet; patients can order it themselves.
Overview
SpeciCare is a US service that arranges for a patient's tumour tissue to be preserved alive at the time of biopsy or surgery, rather than fixed and discarded, so that functional drug testing, organoid growth or future therapies can use it. Future of Cancer Care Today lists it as patient-orderable.
Similar pages
- Company2cureX
Shares Functional (ex vivo) drug testing, Patient-derived organoids and the tag fcct-directory.
- CompanyCure-First
Shares Functional (ex vivo) drug testing, Patient-derived organoids and the tag fcct-directory.
- CompanySageMedic
Shares Functional (ex vivo) drug testing, Patient-derived organoids and the tag fcct-directory.
- CompanyTravera
Shares Functional (ex vivo) drug testing and the tag fcct-directory.
- CompanyKiyatec
Shares Functional (ex vivo) drug testing, Patient-derived organoids and the tag fcct-directory.
- CompanyFirst Ascent Biomedical
Shares Functional (ex vivo) drug testing and the tag fcct-directory.
- CompanyKYAN Technologies
Shares Functional (ex vivo) drug testing and the tag fcct-directory.
- CompanyStoreMyTumor
Shares Functional (ex vivo) drug testing and the tag fcct-directory.